Academic Journal
Known Unknowns: Unpacking Controversies and Uncertainties in the 2025 Guidelines for Management of Acute Coronary Syndromes.
| Τίτλος: | Known Unknowns: Unpacking Controversies and Uncertainties in the 2025 Guidelines for Management of Acute Coronary Syndromes. |
|---|---|
| Συγγραφείς: | Restrepo VJ; From New York University Langone Health System, 550 1stAve, New York, NY, 10016, USA., Rao SV; From New York University Langone Health System, 550 1stAve, New York, NY, 10016, USA. sunil.rao@nyulangone.org. |
| Πηγή: | Current cardiology reports [Curr Cardiol Rep] 2026 Oct 05; Vol. 28 (1). Date of Electronic Publication: 2026 Oct 05. |
| Τύπος έκδοσης: | Journal Article; Review |
| Γλώσσα: | English |
| Στοιχεία περιοδικού: | Publisher: Current Science Country of Publication: United States NLM ID: 100888969 Publication Model: Electronic Cited Medium: Internet ISSN: 1534-3170 (Electronic) Linking ISSN: 15233782 NLM ISO Abbreviation: Curr Cardiol Rep Subsets: MEDLINE |
| Imprint Name(s): | Original Publication: Philadelphia, PA : Current Science, c1999- |
| Ιατρικοί όροι (MeSH): | Acute Coronary Syndrome*/therapy , Percutaneous Coronary Intervention*/methods , ST Elevation Myocardial Infarction*/therapy , Non-ST Elevated Myocardial Infarction*/therapy , Practice Guidelines as Topic*, Recombinant Proteins/therapeutic use ; Peptide Fragments/therapeutic use ; Shock, Cardiogenic/therapy ; Humans ; Hirudins |
| Περίληψη: | Purpose of Review: The 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for managing patients with acute coronary syndromes (ACS) is the first major update since the 2013-2015 ST-elevation myocardial infarction (STEMI) and non-ST elevated myocardial infarction (NSTEMI) guidelines. It brings both conditions together into a single framework. This review covers the most important new and revised recommendations and points out where evidence is still lacking. Recent Findings: New findings show that several significant updates are based on recent large-scale trials. The use of bivalirudin with high-dose infusion after percutaneous coronary intervention (PCI) is now given a Class I recommendation for primary PCI in the case of STEMI, as a result of the BRIGHT-4 trial. Complete revascularization is also now recommended as Class I for stable STEMI patients who have multivessel disease, according to the COMPLETE trial. For a selected group of patients with refractory cardiogenic shock resulting from a myocardial infarction, the percutaneous microaxial flow pump has received a new Class IIa recommendation from the DanGer Shock trial, while the intra-aortic balloon pump and extracorporeal membrane oxygenation are classified as Class III for routine use. Intracoronary imaging (intravascular ultrasound and optical coherence tomography) is now given a Class I recommendation for complex PCI, based on the data of the RENOVATE-COMPLEX-PCI, OCTOBER, and OCTIVUS trials. The guidelines also suggest specific low-density lipoprotein cholesterol (LDL-C) targets, and non-statin drugs should be added if the LDL-C level remains above 70 mg/dL even when maximum statin therapy is used. Regarding antiplatelet therapy, ticagrelor or prasugrel is now preferred to clopidogrel in the case of ACS-PCI, and it is formally recommended to switch to P2Y12 monotherapy at one month in patients at high risk for bleeding as an alternative to standard DAPT. The updates indicate a shift towards more potent antiplatelet therapy at hospital presentation, use of radial access when feasible, more use of imaging-guided PCI, stricter lipid targets, and more refined antiplatelet approaches at the time of discharge. That said, significant gaps in the evidence still exist. It has not yet become clear whether physiology-guided revascularization of non-culprit arteries in patients with STEMI or NSTEMI is better than angiography-guided PCI-a question that is currently being investigated in the randomized COMPLETE-2 trial. The optimal time to provide mechanical circulatory supper in cases of cardiogenic shock remains uncertain. The recent neutral findings from intracoronary imaging studies such as OPTIMAL and IVUS-CHIP might alter the existing Class I recommendation. Lastly, new data from the HOST-EXAM, and SMART CHOICE 3, studies suggest that P2Y12 monotherapy may be better than aspirin for the long-term prevention of major adverse cardiovascular events, and this could influence future guideline recommendations for long term antiplatelet therapies in the chronic phase. (© 2026. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.) |
| Competing Interests: | Declarations. Human and Animal Rights and Informed Consent: This article does not contain any studies with human or animal subjects performed by any of the authors. Conflict of Interest: The authors have no relationships with industry to declare. Use of Artificial Intelligence: The Central Fig. 1 is an AI-generated image. Other AI tools were applied for grammar correction and sentence restructuring. |
| References: | JAMA Cardiol. 2021 Sep 1;6(9):1060-1068. (PMID: 34132735) N Engl J Med. 2024 Apr 18;390(15):1382-1393. (PMID: 38587239) N Engl J Med. 2019 Nov 21;381(21):2032-2042. (PMID: 31556978) Lancet. 2014 Nov 22;384(9957):1849-1858. (PMID: 25002178) N Engl J Med. 2023 Sep 7;389(10):889-898. (PMID: 37634150) J Am Coll Cardiol. 2022 Jan 18;79(2):e21-e129. (PMID: 34895950) Eur Heart J. 2023 Oct 12;44(38):3720-3826. (PMID: 37622654) Lancet. 2024 Sep 7;404(10456):937-948. (PMID: 39226909) J Clin Med. 2025 Apr 26;14(9):. (PMID: 40364024) Lancet. 2024 Mar 2;403(10429):824-837. (PMID: 38401549) JAMA. 2020 Feb 25;323(8):734-745. (PMID: 32040163) N Engl J Med. 2026 Apr 9;394(14):1365-1375. (PMID: 41910315) Circulation. 2013 Jan 29;127(4):e362-425. (PMID: 23247304) N Engl J Med. 2008 May 22;358(21):2218-30. (PMID: 18499566) N Engl J Med. 2012 Oct 4;367(14):1287-96. (PMID: 22920912) J Am Coll Cardiol. 2008 Apr 15;51(15):1440-5. (PMID: 18402897) Eur J Prev Cardiol. 2024 Nov 11;31(15):1806-1816. (PMID: 38788773) JAMA Netw Open. 2024 Jan 2;7(1):e2352427. (PMID: 38270954) N Engl J Med. 2023 Oct 19;389(16):1477-1487. (PMID: 37634149) J Am Coll Cardiol. 2022 Nov 22;80(21):2028-2049. (PMID: 36396205) Lancet. 2022 Nov 26;400(10366):1847-1857. (PMID: 36351459) Am Heart J. 2020 Oct;228:65-71. (PMID: 32866927) N Engl J Med. 2015 Sep 10;373(11):997-1009. (PMID: 26324049) N Engl J Med. 2023 May 4;388(18):1668-1679. (PMID: 36876735) Am J Cardiol. 2022 May 15;171:1-6. (PMID: 35314069) N Engl J Med. 2018 Nov 29;379(22):2097-2107. (PMID: 30403574) Am Heart J. 2018 Aug;202:33-38. (PMID: 29803984) J Am Coll Cardiol. 2024 Oct 15;84(16):1512-1524. (PMID: 39384262) N Engl J Med. 2017 May 4;376(18):1713-1722. (PMID: 28304224) J Am Coll Cardiol. 1993 Sep;22(3):933-40. (PMID: 7689082) Curr Cardiol Rep. 2025 Jul 11;27(1):111. (PMID: 40646403) N Engl J Med. 2023 Oct 5;389(14):1286-1297. (PMID: 37634145) Catheter Cardiovasc Interv. 2025 May;105(6):1523-1529. (PMID: 40077972) JAMA. 2021 Nov 09;326(18):1840-1850. (PMID: 34751704) N Engl J Med. 2019 Oct 10;381(15):1411-1421. (PMID: 31475795) Lancet. 2025 Apr 12;405(10486):1252-1263. (PMID: 40174599) Circulation. 2016 Mar 15;133(11):1135-47. (PMID: 26490017) Circulation. 2014 Dec 23;130(25):e344-426. (PMID: 25249585) N Engl J Med. 2021 Jul 22;385(4):297-308. (PMID: 33999545) Circulation. 2023 Jan 10;147(2):108-117. (PMID: 36342475) Circulation. 2023 Oct 17;148(16):1195-1206. (PMID: 37634092) JACC Cardiovasc Interv. 2022 Mar 28;15(6):656-666. (PMID: 35331458) Am Heart J. 2026 Jul;297:107430. (PMID: 41871678) N Engl J Med. 2023 Oct 12;389(15):1368-1379. (PMID: 37634190) J Am Coll Cardiol. 2025 Jun 10;85(22):2128-2134. (PMID: 40013745) Lancet. 2023 Apr 8;401(10383):1172-1182. (PMID: 36889333) |
| Contributed Indexing: | Keywords: Acute coronary syndrome; Antiplatelet therapy; Cardiogenic shock; Clinical practice guidelines; Intracoronary imaging; Percutaneous coronary intervention |
| Substance Nomenclature: | 0 (Recombinant Proteins) 0 (Hirudins) TN9BEX005G (bivalirudin) 0 (Peptide Fragments) |
| Entry Date(s): | Date Created: 20261005 Date Completed: 20261005 Latest Revision: 20261008 |
| Update Code: | 20261008 |
| DOI: | 10.1007/s11886-026-02427-8 |
| PMID: | 42832065 |
| Βάση Δεδομένων: | MEDLINE |
| ISSN: | 1534-3170 |
|---|---|
| DOI: | 10.1007/s11886-026-02427-8 |